Hypogonadism: A neglected comorbidity in young and middle-aged HIV-positive men on effective combination antiretroviral therapy - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue AIDS. Official journal of the international AIDS Society Année : 2022

Hypogonadism: A neglected comorbidity in young and middle-aged HIV-positive men on effective combination antiretroviral therapy

Résumé

Objective: Male hypogonadism is poorly characterized in young-to-middle-aged people with HIV (PWH). We used a reliable free testosterone assay to assess the prevalence and predictive factors for male hypogonadism in PWH on effective combined antiretroviral therapy (cART).Design:A French cross-sectional study from January 2013 to June 2016.Methods:We included HIV-1-infected men aged between 18 and 50years with HIV loads of 50 RNA copies/ml or less, on effective cART for at least 6 months. Hypogonadism was defined, according to guidelines, as a mean calculated serum free testosterone concentration less than 70pg/ml (Vermeulen equation). Sociodemographic, anthropo-metric, bone-densitometry, hormonal, immunovirological, metabolic, and therapeutic parameters were collected. The IIEF-5, HAM-D, and AMS scales, respectively, assessed erectile function, depression, and quality of life.Results:Overall, 240 patients were enrolled, 231 were analyzed. Low free testosterone concentrations (<70pg/ml) were recorded in 20 patients (8.7%), and were exclusively of secondary origin. In multivariable analysis, the risk factors predictive of male hypogonadism were age more than 43 years [adjusted odds ratio (aOR) 3.17, 95% confidence interval (95% CI) 1.02-9.86;P = 0.04], total fat percentage more than 19% (aOR3.5, 95% CI 1.18-10.37; P = 0.02), and treatment including efavirenz (aOR3.77, 95% CI 1.29-10.98;P=0.02). A nadir CD4+ T-cell count more than 200 cells/μl (aOR 0.22, 95% CI 0.07-0.65;P < 0.01) were protective.Conclusion:Male hypogonadism remains common in young-to-middle-aged PWH with stably suppressed viral replication. Treatment including efavirenz, being over 43 years old, and having a total body fat percentage greater than 19% could be used as criteria for identifying PWH at risk. Early screening for male hypogonadism might improve care by identifying patients requiring testosterone replacement. Copyright
Fichier principal
Vignette du fichier
Hypogonadism__a_neglected_comorbidity_in_young_and.2.pdf (266.93 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03775773 , version 1 (08-11-2022)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Marie Lachâtre, Armelle Pasquet, Faïza Ajana, Benoi̊t C. Soudan, Yann Quertainmont, et al.. Hypogonadism: A neglected comorbidity in young and middle-aged HIV-positive men on effective combination antiretroviral therapy. AIDS. Official journal of the international AIDS Society, 2022, 36 (8), pp.1061-1071. ⟨10.1097/QAD.0000000000003176⟩. ⟨hal-03775773⟩
22 Consultations
32 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More